Small cell lung cancer: New clinical recommendations and current status of biomarker assessment

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Planchard, David ^a   Le Péchoux, Cécile ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMRUBICIN; BEVACIZUMAB; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; NAVITOCLAX; PACLITAXEL; PEMETREXED; PLATINUM; PROTEIN BCL 2; THALIDOMIDE; TOPOTECAN; VANDETANIB; VINCRISTINE;

ALOPECIA; AMNESIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; ATAXIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DEMENTIA; DRUG TREATMENT FAILURE; HEADACHE; HISTOPATHOLOGY; HUMAN; INTELLECTUAL IMPAIRMENT; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; ONCOGENE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROPHYLACTIC CRANIAL IRRADIATION; SEIZURE; SIGNAL TRANSDUCTION; SKULL IRRADIATION; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 80053271947     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70173-3     Document Type: Article

References (65)

1. DM Parkin, F Bray, J Ferlay, P Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. M Sorensen, M Pijls-Johannasma, E Felip, on behalf of the ESMO Guidelines Working Group Small-cell-lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up Ann Oncol 21 Suppl 5 2010 vl20 vl25
3. GR Simon, AT Turrisi III Management of small cell lung cancer. ACCP evidence-based clinical practice guidelines (2nd edn) Chest 132 2007 324S 339S (Pubitemid 47505212)
4. WD Travis, TV Colby, B Corrin World Health Organization Pathology Panel Histological typing of lung and pleural tumors 3rd edn. 1999 World Health Organization
5. FA Shepherd, J Crowley, P Van Houtte et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 2 2007 1067 1077 (Pubitemid 350307898)
6. JP van Meerbeeck, DA Fennell, DK De Ruysscher Small-cell lung cancer Lancet 2011 [Epub ahead of print].
7. J Prins, EG De Vries, NH Mulder The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types Anticancer Res 13 1993 1373 1385 (Pubitemid 23334762)
8. F Cuttitta, DN Carney, J Mulshine et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer Nature 316 1985 823 826 (Pubitemid 15003742)
9. JP Pignon, R Amagada, DC Ihde et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer N Engl J Med 327 1992 1618 1624
10. P Warde, D Payne Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis J Clin Oncol 10 1992 890 895
11. R Amagada, JP Pignon, T Le Chevalier Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer NEnglJMed 345 2001 1281 1282 (Pubitemid 34951498)
12. A Gregor, P Drings, J Burghouts et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study J Clin Oncol 15 1997 2840 2849 (Pubitemid 27330011)
13. B Lebeau, T Urban, JM Brechot et al. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group Cancer 86 1999 1480 1487 (Pubitemid 29489781)
14. M Takada, M Fukuoka, M Kawahara et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J Clin Oncol 20 2002 3054 3060 (Pubitemid 34791094)
15. AT Turrisi 3rd, K Kim, R Blum et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide NEngl JMed 340 1999 265 271 (Pubitemid 29063268)
16. DB Fried, DE Morris, C Poole et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer J Clin Oncol 22 2004 4837 4845
17. D De Ruysscher, M Pijls-Johannesma, J Vansteenkiste et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann Oncol 17 2006 543 552
18. D De Ruysscher, M Pijls-Johannesma, SM Bentzen et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer J Clin Oncol 24 2006 1057 1063 (Pubitemid 46638802)
19. SE Schild, JA Bonner, TG Shanahan et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer Int J Radiat Oncol Biol Phys 59 2004 943 951 (Pubitemid 38834286)
20. NC Choi, JE Herndon 2nd, J Rosenman et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer J Clin Oncol 16 1998 3528 3536 (Pubitemid 28506764)
21. R Komaki, RS Swann, DS Ettinger et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12 Int J Radiat Oncol Biol Phys 62 2005 342 350 (Pubitemid 40704448)
22. P Baas, JS Belderbos, S Senan et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study Br J Cancer 94 2006 625 630 (Pubitemid 43361891)
23. J Van Loon, D De Ruysscher, R Wanders et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study Int J Radiat Oncol Biol Phys 77 2010 326 329
24. S Leyvraz, S Pampallona, G Martinelli for the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial J Nati Cancer Inst 100 2008 533 541
25. A Auperin, R Amagada, JP Pignon et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group N Engl J Med 341 1999 476 484 (Pubitemid 29372887)
26. C Le Péchoux, A Dunant, S Senan et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial Lancet Oncol 10 2009 467 474
27. C Le Péchoux, A Laplanche, C Faivre-Finn et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01) Ann Oncol 22 2011 1154 1163
28. BJ Roth, DH Johnson, LH Einhorn et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group J Clin Oncol 10 1992 282 291
29. C Mascaux, M Paesmans, T Berghmans et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis Lung Cancer 30 2000 23 36
30. JL Pujol, L Carestía, JP Daures Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent Br J Cancer 83 2000 8 15
31. JL Pujol, JP Daures, A Riviere et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study JNatl Cancer Inst 93 2001 300 308 (Pubitemid 32219817)
32. K Noda, Y Nishiwaki, M Kawahara et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91 (Pubitemid 34438898)
33. N Hanna, PA Bunn Jr, C Langer et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2006 2038 2043 (Pubitemid 46622112)
34. PN Lara Jr, R Natale, J Crowley et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2009 2530 2535
35. DV Skarlos, E Samantas, P Kosmidis et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study Ann Oncol 5 1994 601 607 (Pubitemid 24283096)
36. PJ Loehrer Sr, R Ansari, R Gonin et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study J Clin Oncol 13 1995 2594 2599
37. JH Schiller, S Adak, D Celia et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group J Clin Oncol 19 2001 2114 2122 (Pubitemid 32366966)
38. PN Lara Jr, K Chansky, T Shibata et al. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124 Cancer 116 2010 5710 5715
39. J Jiang, X Liang, X Zhou et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer J Thorac Oncol 5 2010 863 867
40. JR Eckardt, J von Pawel, Z Papai et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer J Clin Oncol 24 2006 2044 2051 (Pubitemid 46622113)
41. D Mavroudis, E Papadakis, M Veslemes et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer Ann Oncol 12 2001 463 470 (Pubitemid 32472099)
42. HB Niell, JE Herndon 2nd, AA Miller et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 J Clin Oncol 23 2005 3752 3759
43. MA Socinski, EF Smit, P Lorigan et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer J Clin Oncol 27 2009 4787 4792
44. T Yana, S Negoro, M Takada et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Invest New Drugs 25 2007 253 258 (Pubitemid 46774694)
45. J von Pawel, JH Schiller, FA Shepherd et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 1999 657 658
46. JR Eckardt, J von Pawel, JL Pujol et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer J Clin Oncol 25 2007 2086 2092 (Pubitemid 46972795)
47. ME O'Brien, TE Ciuleanu, H Tsekov et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 2006 5441 5447 (Pubitemid 46623178)
48. A Inoue, S Sugawara, K Yamazaki et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 2008 5401 5406
49. R Jotte, P Conkling, C Reynolds et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 29 2011 287 293
50. DS Ettinger, R Jotte, P Lorigan et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2010 2598 2603
51. JR Jett, AW Maksymiuk, JQ Su et al. Phase III trial of recombinant Interferon gamma in complete responders with small-cell lung cancer J Clin Oncol 12 1994 2321 2326 (Pubitemid 24346702)
52. K Kelly, JJ Crowley, PA Bunn Jr et al. Role of recombinant Interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study J Clin Oncol 13 1995 2924 2930
53. FA Shepherd, G Giaccone, L Seymour et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer J Clin Oncol 20 2002 4434 4439 (Pubitemid 35334754)
54. JL Pujol, JL Breton, R Gervais et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01 J Clin Oncol 25 2007 3945 3951 (Pubitemid 47477272)
55. S Lee, P Woll, L James et al. Etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC) IASLC 2007 PRS P04
56. L Horn, SE Dahlberg, AB Sandler et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501 J Clin Oncol 27 2009 6006 6011
57. N Ready, A Dudek, X Wang et al. CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) JClin Oncol 25 18S 2007 abstract 7563.
58. DR Spigel, FA Greco, JD Zubkus et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer J Thorac Oncol 4 2009 1555 1560
59. AM Arnold, L Seymour, M Smylie et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 J Clin Oncol 25 2007 4278 4284 (Pubitemid 47548568)
60. CM Rudin, R Salgia, X Wang et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 JClin Oncol 26 2008 870 876 (Pubitemid 351398078)
61. L Gandhi, DR Camidge, M Ribeiro de Oliveira et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors JClin Oncol 29 2011 909 916
62. PN Lara Jr, K Chansky, AM Davies et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327) J Thorac Oncol 1 2006 996 1001 (Pubitemid 47181369)
63. AM Moore, LH Einhorn, D Estes et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial Lung Cancer 52 2006 93 97 (Pubitemid 43340205)
64. LM Krug, JP Crapanzano, CG Azzoli et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial Cancer 103 2005 2128 2131 (Pubitemid 40605121)
65. B Slotman, C Faivre-Finn, G Kramer et al. Prophylactic cranial irradiation in extensive small-cell lung cancer N Engl J Med 357 2007 664 672 (Pubitemid 47267236)